CORRELATIONS BETWEEN PERIPHERAL BLOOD INFLAMMATORY MARKERS AND INTERLEUKIN-21 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES-Reference-Cited by-同舟云学术

CORRELATIONS BETWEEN PERIPHERAL BLOOD INFLAMMATORY MARKERS AND INTERLEUKIN-21 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

Published:2022-04-11 Issue: Volume: Page:
ISSN:1512-0392
Container-title:EXPERIMENTAL & CLINICAL MEDICINE GEORGIA
language:
Short-container-title:jecm

Author:

NANAVA NINO,GIORGOBIANI GIORGI,KIKODZE NINO,METREVELI SOPHIO,CHIKOVANI TINATIN,JANIKASHVILI NONA

Abstract

Inflammation that occurs in the tumor microenvironment and in the systemic circulation correlates with disease progression and prognosis in a number of tumors. One way to assess the systemic immune response is to determine the cells/their ratio associated with inflammation, which can easily be measured with complete blood count. IL-21 has a variety of regulatory effects on both normal and tumor cells, leading to their proliferation, differentiation, and apoptosis.The aim of our study was to determine the level of IL-21 in patients with lymphoma-leukemia and to correlate it with the biomarkers of systemic inflammation involved in carcinogenesis - NLR, PLR, PMR, HLR, SII, dNLR.The study included patients with hematologic tumors who underwent splenectomy for therapeutic indications. The control group consisted of patients who also underwent splenectomy but not due to malignant tumor or autoimmune disease.According to our study analysis interleukin-21 levels did not differ significantly between the study and control groups. Serum levels of interleukin-21 in patients with malignant hematologic tumors are negatively correlated with dNLR.

Publisher

Association For Science (Publications)

Reference40 articles.

1. G. J. K. Guthrie, C. S. D. Roxburgh, O. M. Farhan-Alanie, P. G. Horgan, and D. C. McMillan, “Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer,” Br. J. Cancer 2013 1091, vol. 109, no. 1, pp. 24–28, Jun. 2013, doi: 10.1038/bjc.2013.330.

2. J. Candido and T. Hagemann, “Cancer-Related Inflammation,” J. Clin. Immunol. 2012 331, vol. 33, no. 1, pp. 79–84, Dec. 2012, doi: 10.1007/S10875-012-9847-0.

3. C. Servais and N. Erez, “From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation,” J. Pathol., vol. 229, no. 2, pp. 198–207, Jan. 2013, doi: 10.1002/PATH.4103.

4. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nat. 2002 4206917, vol. 420, no. 6917, pp. 860–867, Dec. 2002, doi: 10.1038/nature01322.

5. A. Stoppacciaro et al., “Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.,” J. Exp. Med., vol. 178, no. 1, pp. 151–161, Jul. 1993, doi: 10.1084/JEM.178.1.151.